These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 12876902

  • 1. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia.
    Morales A, Arias Salazar J, Salazar Y, García A, Arnoux S, Arancibia A, Deroche C, Rey E.
    Medicina (B Aires); 2003; 63(3):197-204. PubMed ID: 12876902
    [Abstract] [Full Text] [Related]

  • 2. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.
    Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, Giezeman K, de Bruijn I.
    Vaccine; 2008 Aug 18; 26(35):4579-84. PubMed ID: 18602729
    [Abstract] [Full Text] [Related]

  • 4. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 5. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 15; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 6. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 15; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 7. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 8. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 16; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

  • 9. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 10. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B, Fletcher MA, Valette M, Saliou P, Aymard M.
    Biologicals; 2000 Jun 27; 28(2):95-103. PubMed ID: 10885616
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
    Souza AR, Braga JA, de Paiva TM, Loggetto SR, Azevedo RS, Weckx LY.
    Vaccine; 2010 Jan 22; 28(4):1117-20. PubMed ID: 20116631
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 13. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM.
    Vaccine; 2005 Jul 08; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 08; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.
    J Infect Dis; 2009 Sep 15; 200(6):841-8. PubMed ID: 19673651
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 17. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.
    N Engl J Med; 2004 Nov 25; 351(22):2295-301. PubMed ID: 15525714
    [Abstract] [Full Text] [Related]

  • 18. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 25; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Sep 25; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.